Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.
- DOI
- 10.1182/bloodadvances.2025016399
- Published
- 2025 Oct 28
- Container
- Blood advances
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1182/bloodadvances.2025016399,
title = {Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.},
author = {Montesinos P and Marchione DM and Recher C and Heuser M and Vives S and Zarzycka E and Wang J and Riva M and Calado RT and Schuh AC and Yeh SP and Tron AE and Hui J and Gianolio DA and Choe S and Patel P and De Botton S and DiNardo CD and Döhner H},
year = {2025},
journal = {Blood advances},
doi = {10.1182/bloodadvances.2025016399},
url = {https://doi.org/10.1182/bloodadvances.2025016399}
}RIS
TY - JOUR TI - Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML. AU - Montesinos P AU - Marchione DM AU - Recher C AU - Heuser M AU - Vives S AU - Zarzycka E AU - Wang J AU - Riva M AU - Calado RT AU - Schuh AC AU - Yeh SP AU - Tron AE AU - Hui J AU - Gianolio DA AU - Choe S AU - Patel P AU - De Botton S AU - DiNardo CD AU - Döhner H PY - 2025 JO - Blood advances DO - 10.1182/bloodadvances.2025016399 UR - https://doi.org/10.1182/bloodadvances.2025016399 ER -
APA
P, M., DM, M., C, R., M, H., S, V., E, Z., J, W., M, R., RT, C., AC, S., SP, Y., AE, T., J, H., DA, G., S, C., P, P., S, D. B., CD, D., & H, D. (2025). Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.. Blood advances. https://doi.org/10.1182/bloodadvances.2025016399
Source records
- pubmed · retrieved 2026-09-26T17:37:54.780Z